This trial is evaluating whether mRNA-1273.351 will improve 8 primary outcomes and 2 secondary outcomes in patients with COVID-19. Measurement will happen over the course of Through 7 days post-vaccination.
This trial requires 135 total participants across 10 different treatment groups
This trial involves 10 different treatments. MRNA-1273.351 is the primary treatment being studied. Participants will be divided into 10 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
Participation is compensated
You will be compensated for participating in this trial.
The new RNA-1273.351 drug candidate has been demonstrated in several studies to possess an effective antitumoral effect against several types of cancers, including multiple myeloma and leukoplakia. Further exploration of this lead molecule is warranted. We demonstrated a direct connection between the anticancer effects of mrna-1273.351 and a potent up-regulation of interferon induced genes (IIGs).
The expression of mRNA-1273.351 in EOC cells is enhanced by the combination of cisplatin and paclitaxel, and may mediate EOC cell resistance to these agents.
In the United States, the current rate of new cases of COVID-19 is 3.5 cases per 100,000 population, and death has occurred in 1.08 cases per 100,000 population. Over the last 100 days, there have been no reported U.S deaths, with an average incidence of the virus in the United States of 0.3 cases per 100,000 population per day.
Signs of covid-19 illness include fever. The most common symptom includes a cough, which, in turn, leads to symptoms such as malaise, fatigue, headache and a runny or stuffy nose. Patients may also experience shortness of breath, headaches, erythema rashes, muscle aches, dizziness and chest congestion, which is why patients must be evaluated urgently.\n
Based on the available evidence, it is unlikely that a single novel coronavirus infection will be able to permanently eliminate the virus from the population. It is possible, however, that the virus can temporarily stop spreading in humans. The duration of this period is very unlikely to be less than one year. As such, the disease would not be a permanent, eradicated, and theoretically cureable condition.
It is a highly contagious disease that can be transmitted through cough droplets, sneezes, saliva, fecal matter or direct contact, or in rare instances via bodily fluids from an infected person. Although the virus spread in the population, the exact course of infection and severity of illness remains unknown. Although the virus spread in the population, the exact course of infection and severity of illness remains unknown. The virus has not been shown to be transmissible via airborne transmission.\n
The first case of the new coronavirus outbreak in Egypt is of a 57-year-old Egyptian man. Symptoms were absent in this case compared with a study published in The Lancet by the same authors in which a 53-year-old Chinese man and a 26-year-old Indian man had also been infected. Both the first case and the study reported that they were symptomatic. The initial diagnosis of the latter case was made by the presence of a fever and acute respiratory distress syndrome. Most cases of the virus showed no symptoms. The virus is spread through respiratory droplets made in the coughing and sneezing of infected persons.
The prevention and treatment of Covid-19 are dependent on which patient is affected. There are a variety of methods of prevention and treatment including pharmacotherapies and lifestyle changes. There is no clear guideline for treatment of patients with preexistent illnesses. There is no firm evidence regarding efficacy or safety regarding potential treatments for those infected with coronavirus. It is expected that new developments will reveal new methods to treat affected patients in the future.
Data from a recent study suggests that the 1273.351 sequence may have therapeutic effect on MHC II deficiency syndrome via upregulation of MHC II expression.
Clinical trials are urgently needed to help researchers identify effective treatments for patients with mild symptoms of viral infection. Patient groups who have a greater likelihood of participating in clinical trials include patients who are younger, healthier individuals, and those with no underlying conditions.
In the U.S., the average age someone gets covid-19 is 68 and among those aged 65 and older, it's about 3% who die. The actual age at which someone dies in the U.S. is about 8% younger due to people who start dying right after their diagnosis and due to people who are dying due to factors other than covid-19: heart disease is the most frequent cause of death for people with covid-19. However, health policy experts, who are more likely to be of a younger age, are more likely to think that the aging population will have a large impact when a spike in deaths due to covid-19 first appear here in the U.S.
This novel target is uniquely expressed in the human immune system and is involved in the control of autoimmune disease, ankylosing spondylitis, and Crohn disease. The ability of the VEPR2 gene to initiate and sustain disease implicates it as a potential drug target in chronic autoimmune disorders. We investigated the effect of VEPR2 RNAi on human immune cell functions. In a recent study, findings provides evidence that VEPR2 is a safe new drug target that could modify or regulate the immune response in immune-related diseases using new drug discovery tools in preclinical studies to inform clinical trials.